WuXi AppTec Co., Ltd. Class H (HK:2359)
:2359
2359 Stock Chart & Stats
HK$124.90
HK$1.65(3.23%)
At close: 4:00 PM EST
HK$124.90
HK$1.65(3.23%)
Day’s Range― - ―
52-Week RangeHK$44.30 - HK$129.90
Previous CloseN/A
Volume2.88M
Average Volume (3M)6.08M
Market Cap
HK$337.15B
Enterprise ValueHK$226.25B
Total Cash (Recent Filing)HK$40.94B
Total Debt (Recent Filing)HK$8.26B
Price to Earnings (P/E)13.2
Beta1.60
Next Earnings
Apr 28, 2026EPS Estimate
1.39Next Dividend Ex-DateN/A
Dividend Yield1.84%
Share Statistics
EPS (TTM)2.87
Shares Outstanding510,476,900
10 Day Avg. Volume5,559,442
30 Day Avg. Volume6,076,831
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)3.18
Price to Sales (P/S)5.57
P/FCF Ratio21.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$152.04Price Target Upside21.73% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)6.63
Revenue Forecast (FY)HK$59.55B
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet And Low LeverageWuXi’s low reported leverage and large equity base provide durable financial flexibility to fund multi-year capacity buildouts, sustain a 30% payout policy, and absorb cyclical cash swings. This conservatism supports investment in CDMO/TIDES capex and shields operations from episodic funding stress.
Sustained Margin Expansion And Strong ProfitabilityMaterial, persistent margin improvement reflects higher operational leverage, mix shift to higher-margin chemistry and TIDES work, and cost efficiencies. Strong non-IFRS margins underpin robust free cash flow generation capacity and increase ability to self-fund growth and return capital over multiple years.
Large Backlog And Capacity Expansion Underpin VisibilityA sizable, growing backlog plus targeted capacity additions (APIs, peptide synthesizers) provide multi-quarter revenue visibility and convertibility. This structural orderbook supports the company’s 2026 guidance and gives durable upside to utilization, smoothing revenue recognition as projects progress into development and commercial stages.
Bears Say
Top-line Volatility And Forecasting UncertaintyRevenue has shown material year-to-year swings driven by timing of project deliveries and regional variability. This structural variability increases forecasting risk for multi-quarter planning, complicates capacity planning and working-capital management, and can amplify margin and cash flow volatility despite underlying demand.
Rising Inventory And Working-capital PressureHigher inventory tied to longer manufacturing cycles and pre-stocking for big programs ties up cash and delays cash conversion. Persistently elevated inventories can pressure free cash flow and require higher financing or slower dividend increases, particularly as the company scales multi-site CDMO output over the next 2–3 years.
Modality Concentration And External Competitive/policy RisksRapid revenue concentration in peptides/TIDES and exposure to GLP-1 demand heighten vulnerability if modality growth slows or pricing shifts. Concurrent competitive pressure in oligonucleotide CDMO and unresolved policy/geo-risks (e.g., regulatory lists) could limit pricing power and future margin sustainability across key segments.
WuXi AppTec Co., Ltd. Class H News
2359 FAQ
What was WuXi AppTec Co., Ltd. Class H’s price range in the past 12 months?
WuXi AppTec Co., Ltd. Class H lowest stock price was HK$44.30 and its highest was HK$129.90 in the past 12 months.
What is WuXi AppTec Co., Ltd. Class H’s market cap?
WuXi AppTec Co., Ltd. Class H’s market cap is HK$337.15B.
When is WuXi AppTec Co., Ltd. Class H’s upcoming earnings report date?
WuXi AppTec Co., Ltd. Class H’s upcoming earnings report date is Apr 28, 2026 which is in 20 days.
How were WuXi AppTec Co., Ltd. Class H’s earnings last quarter?
WuXi AppTec Co., Ltd. Class H released its earnings results on Mar 23, 2026. The company reported HK$2.866 earnings per share for the quarter, missing the consensus estimate of HK$2.983 by -HK$0.117.
Is WuXi AppTec Co., Ltd. Class H overvalued?
According to Wall Street analysts WuXi AppTec Co., Ltd. Class H’s price is currently Undervalued.
Does WuXi AppTec Co., Ltd. Class H pay dividends?
WuXi AppTec Co., Ltd. Class H pays a Annually dividend of HK$0.385 which represents an annual dividend yield of 1.84%. See more information on WuXi AppTec Co., Ltd. Class H dividends here
What is WuXi AppTec Co., Ltd. Class H’s EPS estimate?
WuXi AppTec Co., Ltd. Class H’s EPS estimate is 1.39.
How many shares outstanding does WuXi AppTec Co., Ltd. Class H have?
WuXi AppTec Co., Ltd. Class H has 510,476,900 shares outstanding.
What happened to WuXi AppTec Co., Ltd. Class H’s price movement after its last earnings report?
WuXi AppTec Co., Ltd. Class H reported an EPS of HK$2.866 in its last earnings report, missing expectations of HK$2.983. Following the earnings report the stock price went down -4.019%.
Which hedge fund is a major shareholder of WuXi AppTec Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2359
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
WuXi AppTec Co., Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
118.09%
12-Months-Change
Fundamentals
Return on Equity
23.81%
Trailing 12-Months
Asset Growth
25.81%
Trailing 12-Months
Company Description
WuXi AppTec Co., Ltd. Class H
WuXi AppTec Co., Ltd., an investment holding company, provides research, development, and manufacturing services to discover, develop, and manufacture small molecule drugs, and cell and gene therapies in the People's Republic of China, rest of Asia, the United States, Europe, and internationally. The company operates through six segments: WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and Others. It offers contract research, development, and manufacturing organization services for new drug development from discovery to commercial covering various categories for various synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates; and biology services and solutions that support stand-alone and integrated projects from target discovery to candidate selection and into the clinic. The company also provides seamless drug and medical device testing services from preclinical testing to clinical trials; an integrated end-to-end solution to accelerate time to market for cell and gene therapies; drug discovery services to pharmaceutical and biotech customers; and clinical research services. WuXi AppTec Co., Ltd. was founded in 2000 and is headquartered in Shanghai, the People's Republic of China.
2359 Stock 12 Month Forecast
Average Price Target
HK$152.04
▲(21.73% Upside)
Technical Analysis
Wuxi Biologics (Cayman)
―
Hangzhou Tigermed Consulting Co., Ltd. Class H
―
Pharmaron Beijing Co., Ltd. Class H
―
Hansoh Pharmaceutical Group Company Limited
―
WuXi XDC Cayman, Inc.
―
Options Prices
Currently, No data available
---